X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VP-315 (ruxotemitide)is a potential first-in-class oncolytic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death. It is under phase 2 clinical development for the treatment of Basal Cell Carcinoma.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: VP-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2024
Details:
VP-315 (ruxotemitide, formerly known as LTX 315) is a potential first-in-class oncolytic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death, which may offer a non-surgical option for patients suffering from skin cancer.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: VP-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
The trial demonstrated that combination of LTX-315 and ACT is feasible and tolerable, and that CD4+ and CD8+ T cells can be expanded in vitro from STS that have been pretreated with the oncolytic molecule LTX-315.
Lead Product(s): Ruxotemitide,Adoptive Cell Therapy
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death, which also has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.
Lead Product(s): Ruxotemitide,Tumour Infiltrating Lymphocytes
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Verrica, has an exclusive license agreement with Lytix to develop and commercialize LTX-315 for skin cancer conditions. LTX-315 is a first-in-class oncolytic peptide derived from human lactoferrin, with potential lytic and immunostimulating activities.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Verrica Pharmaceuticals
Deal Size: $111.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 05, 2022
Details:
LTX-315, a potential first-in-class oncolytic peptide directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery, for the treatment of basal cell carcinoma.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
The licensing agreement is focused on developing and commercializing LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development.
Lead Product(s): Ruxotemitide
Therapeutic Area: Oncology Product Name: LTX-315
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Verrica Pharmaceuticals
Deal Size: $113.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
